Geoff Meacham
Stock Analyst at B of A Securities
(3.61)
# 984
Out of 4,496 analysts
156
Total ratings
52.1%
Success rate
4.81%
Average return
Main Sectors:
57 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LYEL Lyell Immunopharma | Maintains: Buy | $9 → $6 | $1.56 | +284.62% | 2 | Jun 27, 2024 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $50 → $42 | $26.19 | +60.37% | 3 | Jun 25, 2024 | |
| LLY Eli Lilly | Maintains: Buy | $1,000 | $857.47 | +16.62% | 7 | Jun 24, 2024 | |
| RNA Avidity Biosciences | Maintains: Buy | $40 → $45 | $45.12 | -0.27% | 2 | Jun 13, 2024 | |
| APGE Apogee Therapeutics | Initiates: Buy | $80 | $47.50 | +68.42% | 1 | May 10, 2024 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $180 → $170 | $154.69 | +9.90% | 2 | Apr 17, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Underperform | $710 → $720 | $1,063.60 | -32.31% | 4 | Apr 12, 2024 | |
| RPRX Royalty Pharma | Maintains: Buy | $40 → $38 | $28.14 | +35.04% | 2 | Apr 12, 2024 | |
| BIIB Biogen | Maintains: Neutral | $280 → $260 | $226.40 | +14.84% | 9 | Apr 12, 2024 | |
| BTAI BioXcel Therapeutics | Maintains: Buy | $8 → $7 | $1.17 | +498.29% | 3 | Mar 13, 2024 | |
| JANX Janux Therapeutics | Maintains: Buy | $24 → $48 | $44.68 | +7.43% | 2 | Mar 13, 2024 | |
| KYMR Kymera Therapeutics | Downgrades: Neutral | $45 → $30 | $43.10 | -30.39% | 3 | Jan 3, 2024 | |
| BMY Bristol-Myers Squibb Company | Downgrades: Neutral | $68 → $60 | $42.64 | +40.71% | 7 | Jan 3, 2024 | |
| IGMS IGM Biosciences | Downgrades: Neutral | $8 | $10.74 | -25.51% | 2 | Dec 15, 2023 | |
| AMGN Amgen | Reinstates: Neutral | $290 | $331.29 | -12.46% | 6 | Oct 11, 2023 | |
| NMRA Neumora Therapeutics | Initiates: Buy | $18 | $11.28 | +59.57% | 1 | Oct 10, 2023 | |
| VIR Vir Biotechnology | Downgrades: Neutral | $23 → $14 | $10.03 | +39.58% | 2 | Sep 8, 2023 | |
| GILD Gilead Sciences | Upgrades: Buy | $88 → $95 | $72.56 | +30.93% | 5 | Sep 8, 2023 | |
| CVAC CureVac | Maintains: Underperform | $10 → $8 | $3.67 | +117.98% | 4 | Aug 21, 2023 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $19 → $17 | $3.08 | +451.95% | 1 | Aug 21, 2023 | |
| TSBX Turnstone Biologics | Initiates: Buy | $18 | $2.37 | +659.49% | 1 | Aug 15, 2023 | |
| MRNA Moderna | Maintains: Neutral | $175 → $150 | $121.14 | +23.82% | 5 | Aug 4, 2023 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $200 → $185 | $84.09 | +120.00% | 1 | Jul 21, 2023 | |
| ABOS Acumen Pharmaceuticals | Reinstates: Buy | $14 | $2.87 | +387.80% | 3 | Jul 20, 2023 | |
| PFE Pfizer | Maintains: Neutral | $50 → $45 | $29.97 | +50.15% | 6 | Apr 21, 2023 | |
| AMLX Amylyx Pharmaceuticals | Initiates: Buy | $50 | $2.02 | +2,375.25% | 1 | Jan 5, 2023 | |
| MRK Merck & Co. | Upgrades: Buy | $110 → $130 | $125.77 | +3.36% | 5 | Jan 4, 2023 | |
| ABBV AbbVie | Maintains: Neutral | $162 → $165 | $172.32 | -4.25% | 11 | Dec 14, 2022 | |
| INO Inovio Pharmaceuticals | Downgrades: Underperform | $24 | $10.07 | +138.33% | 4 | Nov 1, 2022 | |
| OMER Omeros | Downgrades: Neutral | $12 → $4 | $4.88 | -18.03% | 2 | Jun 8, 2022 | |
| KNSA Kiniksa Pharmaceuticals | Maintains: Buy | $37 → $34 | $21.23 | +60.15% | 2 | Dec 29, 2021 | |
| VAXX Vaxxinity | Initiates: Buy | n/a | $0.11 | - | 1 | Dec 6, 2021 | |
| TYRA Tyra Biosciences | Initiates: Buy | n/a | $19.73 | - | 1 | Oct 11, 2021 | |
| IPSC Century Therapeutics | Initiates: Buy | n/a | $2.50 | - | 1 | Jul 13, 2021 | |
| YMAB Y-mAbs Therapeutics | Upgrades: Buy | $56 | $11.59 | +383.18% | 3 | May 7, 2021 | |
| ESPR Esperion Therapeutics | Downgrades: Neutral | n/a | $2.39 | - | 2 | Jan 15, 2021 | |
| GLTO Galecto | Initiates: Buy | n/a | $0.56 | - | 1 | Nov 23, 2020 | |
| PMVP PMV Pharmaceuticals | Initiates: Buy | n/a | $1.56 | - | 1 | Oct 20, 2020 | |
| CRSP CRISPR Therapeutics AG | Initiates: Buy | n/a | $54.56 | - | 1 | Oct 5, 2020 | |
| MGTX MeiraGTx Holdings | Reinstates: Buy | n/a | $4.42 | - | 1 | Sep 15, 2020 | |
| SGMO Sangamo Therapeutics | Reinstates: Buy | n/a | $0.40 | - | 1 | Sep 8, 2020 | |
| PSTX Poseida Therapeutics | Initiates: Buy | n/a | $3.06 | - | 1 | Aug 4, 2020 | |
| PBYI Puma Biotechnology | Reinstates: Underperform | n/a | $3.66 | - | 1 | Jun 25, 2020 | |
| RGNX REGENXBIO | Reinstates: Buy | n/a | $12.58 | - | 1 | Jun 25, 2020 | |
| GNFT Genfit | Initiates: Underperform | n/a | $4.16 | - | 1 | Jun 25, 2020 | |
| UTHR United Therapeutics | Maintains: Underweight | n/a | $329.16 | - | 2 | Mar 1, 2019 | |
| DBVT DBV Technologies | Downgrades: Equal-Weight | $60 → $16 | $0.84 | +1,804.76% | 3 | Dec 20, 2018 | |
| PTCT PTC Therapeutics | Maintains: Equal-Weight | n/a | $32.63 | - | 7 | Nov 6, 2018 | |
| GRTS Gritstone bio | Initiates: Overweight | n/a | $0.65 | - | 1 | Oct 23, 2018 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | n/a | $145.69 | - | 2 | Aug 1, 2018 | |
| PRTA Prothena Corporation | Downgrades: Underweight | n/a | $23.58 | - | 2 | May 21, 2018 | |
| ZYME Zymeworks | Upgrades: Equal-Weight | n/a | $9.78 | - | 2 | May 11, 2018 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Equal-Weight | n/a | $6.72 | - | 1 | May 3, 2018 | |
| INCY Incyte | Maintains: Overweight | n/a | $65.87 | - | 2 | Apr 5, 2018 | |
| BHVN Biohaven Pharmaceutical Holding Company | Downgrades: Equal-Weight | n/a | $35.98 | - | 2 | Apr 5, 2018 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | n/a | $491.57 | - | 2 | Feb 1, 2018 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Overweight | n/a | $237.83 | - | 4 | Nov 8, 2017 |
Lyell Immunopharma
Jun 27, 2024
Maintains: Buy
Price Target: $9 → $6
Current: $1.56
Upside: +284.62%
BridgeBio Pharma
Jun 25, 2024
Maintains: Buy
Price Target: $50 → $42
Current: $26.19
Upside: +60.37%
Eli Lilly
Jun 24, 2024
Maintains: Buy
Price Target: $1,000
Current: $857.47
Upside: +16.62%
Avidity Biosciences
Jun 13, 2024
Maintains: Buy
Price Target: $40 → $45
Current: $45.12
Upside: -0.27%
Apogee Therapeutics
May 10, 2024
Initiates: Buy
Price Target: $80
Current: $47.50
Upside: +68.42%
Johnson & Johnson
Apr 17, 2024
Maintains: Neutral
Price Target: $180 → $170
Current: $154.69
Upside: +9.90%
Regeneron Pharmaceuticals
Apr 12, 2024
Maintains: Underperform
Price Target: $710 → $720
Current: $1,063.60
Upside: -32.31%
Royalty Pharma
Apr 12, 2024
Maintains: Buy
Price Target: $40 → $38
Current: $28.14
Upside: +35.04%
Biogen
Apr 12, 2024
Maintains: Neutral
Price Target: $280 → $260
Current: $226.40
Upside: +14.84%
BioXcel Therapeutics
Mar 13, 2024
Maintains: Buy
Price Target: $8 → $7
Current: $1.17
Upside: +498.29%
Janux Therapeutics
Mar 13, 2024
Maintains: Buy
Price Target: $24 → $48
Current: $44.68
Upside: +7.43%
Kymera Therapeutics
Jan 3, 2024
Downgrades: Neutral
Price Target: $45 → $30
Current: $43.10
Upside: -30.39%
Bristol-Myers Squibb Company
Jan 3, 2024
Downgrades: Neutral
Price Target: $68 → $60
Current: $42.64
Upside: +40.71%
IGM Biosciences
Dec 15, 2023
Downgrades: Neutral
Price Target: $8
Current: $10.74
Upside: -25.51%
Amgen
Oct 11, 2023
Reinstates: Neutral
Price Target: $290
Current: $331.29
Upside: -12.46%
Neumora Therapeutics
Oct 10, 2023
Initiates: Buy
Price Target: $18
Current: $11.28
Upside: +59.57%
Vir Biotechnology
Sep 8, 2023
Downgrades: Neutral
Price Target: $23 → $14
Current: $10.03
Upside: +39.58%
Gilead Sciences
Sep 8, 2023
Upgrades: Buy
Price Target: $88 → $95
Current: $72.56
Upside: +30.93%
CureVac
Aug 21, 2023
Maintains: Underperform
Price Target: $10 → $8
Current: $3.67
Upside: +117.98%
Rani Therapeutics Holdings
Aug 21, 2023
Maintains: Buy
Price Target: $19 → $17
Current: $3.08
Upside: +451.95%
Turnstone Biologics
Aug 15, 2023
Initiates: Buy
Price Target: $18
Current: $2.37
Upside: +659.49%
Moderna
Aug 4, 2023
Maintains: Neutral
Price Target: $175 → $150
Current: $121.14
Upside: +23.82%
BioMarin Pharmaceutical
Jul 21, 2023
Maintains: Buy
Price Target: $200 → $185
Current: $84.09
Upside: +120.00%
Acumen Pharmaceuticals
Jul 20, 2023
Reinstates: Buy
Price Target: $14
Current: $2.87
Upside: +387.80%
Pfizer
Apr 21, 2023
Maintains: Neutral
Price Target: $50 → $45
Current: $29.97
Upside: +50.15%
Amylyx Pharmaceuticals
Jan 5, 2023
Initiates: Buy
Price Target: $50
Current: $2.02
Upside: +2,375.25%
Merck & Co.
Jan 4, 2023
Upgrades: Buy
Price Target: $110 → $130
Current: $125.77
Upside: +3.36%
AbbVie
Dec 14, 2022
Maintains: Neutral
Price Target: $162 → $165
Current: $172.32
Upside: -4.25%
Inovio Pharmaceuticals
Nov 1, 2022
Downgrades: Underperform
Price Target: $24
Current: $10.07
Upside: +138.33%
Omeros
Jun 8, 2022
Downgrades: Neutral
Price Target: $12 → $4
Current: $4.88
Upside: -18.03%
Kiniksa Pharmaceuticals
Dec 29, 2021
Maintains: Buy
Price Target: $37 → $34
Current: $21.23
Upside: +60.15%
Vaxxinity
Dec 6, 2021
Initiates: Buy
Price Target: n/a
Current: $0.11
Upside: -
Tyra Biosciences
Oct 11, 2021
Initiates: Buy
Price Target: n/a
Current: $19.73
Upside: -
Century Therapeutics
Jul 13, 2021
Initiates: Buy
Price Target: n/a
Current: $2.50
Upside: -
Y-mAbs Therapeutics
May 7, 2021
Upgrades: Buy
Price Target: $56
Current: $11.59
Upside: +383.18%
Esperion Therapeutics
Jan 15, 2021
Downgrades: Neutral
Price Target: n/a
Current: $2.39
Upside: -
Galecto
Nov 23, 2020
Initiates: Buy
Price Target: n/a
Current: $0.56
Upside: -
PMV Pharmaceuticals
Oct 20, 2020
Initiates: Buy
Price Target: n/a
Current: $1.56
Upside: -
CRISPR Therapeutics AG
Oct 5, 2020
Initiates: Buy
Price Target: n/a
Current: $54.56
Upside: -
MeiraGTx Holdings
Sep 15, 2020
Reinstates: Buy
Price Target: n/a
Current: $4.42
Upside: -
Sangamo Therapeutics
Sep 8, 2020
Reinstates: Buy
Price Target: n/a
Current: $0.40
Upside: -
Poseida Therapeutics
Aug 4, 2020
Initiates: Buy
Price Target: n/a
Current: $3.06
Upside: -
Puma Biotechnology
Jun 25, 2020
Reinstates: Underperform
Price Target: n/a
Current: $3.66
Upside: -
REGENXBIO
Jun 25, 2020
Reinstates: Buy
Price Target: n/a
Current: $12.58
Upside: -
Genfit
Jun 25, 2020
Initiates: Underperform
Price Target: n/a
Current: $4.16
Upside: -
United Therapeutics
Mar 1, 2019
Maintains: Underweight
Price Target: n/a
Current: $329.16
Upside: -
DBV Technologies
Dec 20, 2018
Downgrades: Equal-Weight
Price Target: $60 → $16
Current: $0.84
Upside: +1,804.76%
PTC Therapeutics
Nov 6, 2018
Maintains: Equal-Weight
Price Target: n/a
Current: $32.63
Upside: -
Gritstone bio
Oct 23, 2018
Initiates: Overweight
Price Target: n/a
Current: $0.65
Upside: -
Neurocrine Biosciences
Aug 1, 2018
Maintains: Overweight
Price Target: n/a
Current: $145.69
Upside: -
Prothena Corporation
May 21, 2018
Downgrades: Underweight
Price Target: n/a
Current: $23.58
Upside: -
Zymeworks
May 11, 2018
Upgrades: Equal-Weight
Price Target: n/a
Current: $9.78
Upside: -
Ironwood Pharmaceuticals
May 3, 2018
Maintains: Equal-Weight
Price Target: n/a
Current: $6.72
Upside: -
Incyte
Apr 5, 2018
Maintains: Overweight
Price Target: n/a
Current: $65.87
Upside: -
Biohaven Pharmaceutical Holding Company
Apr 5, 2018
Downgrades: Equal-Weight
Price Target: n/a
Current: $35.98
Upside: -
Vertex Pharmaceuticals
Feb 1, 2018
Maintains: Overweight
Price Target: n/a
Current: $491.57
Upside: -
Alnylam Pharmaceuticals
Nov 8, 2017
Maintains: Overweight
Price Target: n/a
Current: $237.83
Upside: -